Copyright © 2021. Inderes Oyj. All rights reserved.

Genovis AB

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
13.8.
2021

Redeye returns with a follow-up note to Genovis’ Q2’21 report and continues to have a positive long-term view of the case.

Muut analyysit
12.8.
2021

Redeye regards Genovis’ Q2’21 report as solid and finds it encouraging to see continued high growth in the core Analytics segment.

Tiedotteet
12.8.
2021
Second quarter 2021    
  • Net sales rose by 26% to SEK 19,535 (15,490) thousand. Growth is 37%, adjusted for currency effects.
  • Gross profit rose by 32% to SEK 17,365 (13,146) thousand.
  • Operating profit before depreciation and amortization (EBITDA) totaled SEK 2,793 (loss: 38) thousand.
  • Operating profit improved by SEK 2,641 thousand and totaled SEK 1,350 (loss: 1,291) thousand.
  • Comprehensive income for the period improved by SEK 4,156 thousand and totaled SEK 1,033 (loss: 3,123) thousand.
  • Comprehensive income per share, basic and diluted,
Muut analyysit
9.6.
2021

In this note, Redeye elaborates on why we see the cross-licensing agreement with GlycoT Therapeutics as strategically interesting.

Tiedotteet
7.6.
2021

Under the agreements, the combined proprietary technology platform will enable Genovis and GlycoT Therapeutics ("GlycoT") to market, sell and further develop enzymatic workflows for the research and diagnostics markets as well as for therapeutic applications.

Tiedotteet
20.5.
2021

The Annual General Meeting adopted the following resolutions:

  • The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.

  • The Board and the Chief Executive Officer were discharged from liability.

  • The Board shall consist until the next AGM of five ordinary members without deputies.

  • Re-election of Board membersTorben Jørgensen,Mikael Lönn, Kenth Petersson and Lotta Ljungqvist.

Steve Jordanwas elected new Board member.

Muut analyysit
30.4.
2021

Redeye provides a follow-up note to Genovis Q1'21 report, with updated estimates and valuation.

Muut analyysit
29.4.
2021

Redeye’s first impression of Genovis Q1’21 is that it is a pretty solid report in the core business, given that customer activity remains regionally sluggish due to the pandemic.

Tiedotteet
29.4.
2021

First quarter in brief

  •                     Net sales rose by 37 percent to SEK 15,723 (11,475) thousand. Organic growth was 21%.

  •                     Gross profit was SEK 15,017 (10,977) thousand.

  •                     Operating profit before depreciation and amortization (EBITDA) totaled SEK 1,958 (loss: 847) thousand.

  •                     Operating profit totaled SEK 551 (loss: 1,889) thousand.

  •                     Comprehensive income for the period totaled SEK 1,607 (loss: 1,915) thousand.

Tiedotteet
28.4.
2021

Genovis 2020 Annual Report is now available in Swedish and English at our website.

To read or download the annual report in Swedish, go to:

https://investor.genovis.com/wp-content/uploads/genovis-arsredovisning-2020.pdf

To read or download the annual report in English, go to:

https://investor.genovis.com/wp-content/uploads/genovis-annual-report-2020.pdf

Genovis AB